IL-17F Inhibitors & Biosimilars
1 drugsAbout IL-17F
Interleukin-17F (IL-17F) is a cytokine and member of the IL-17 family, playing a crucial role in inflammatory responses and contributing to the pathogenesis of various immune-mediated diseases.
IL-17F is a therapeutic target for immunological disorders, though currently there is no genetic evidence directly linking IL-17F to specific diseases.
IL-17F is targeted by one FDA-approved biologic drug, BIMZELX (UCB INC), indicated for immunology; it was first approved in 2023.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Palmoplantar Pustulosis with only 1 trials.
- phase4 represents biological uncertainty with 50% completion.
Top Drugs
The competitive landscape is dominated by UCB INC, the sole company with an approved drug.
High market concentration indicates potential entry barriers and the need for differentiated therapeutic strategies.
Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets IL-17F, using biologic (other) modality.
The lack of modality diversity suggests an opportunity for small molecule or antibody-based therapeutics targeting IL-17F.
Clinical Trials 58 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 13 | 9 | 1 | 3 | 90% |
| Phase 2 | 14 | 12 | 0 | 2 | 100% |
| Phase 3 | 25 | 16 | 0 | 9 | 100% |
| Phase 4 | 6 | 2 | 2 | 2 | 50% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Drug Approval Timeline (2023 - 2023)
The first drug targeting IL-17F, BIMZELX, was approved in 2023.
Recent approval suggests an emerging target, but further approvals are needed to confirm long-term viability.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (12 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 52 clinical trials targeting IL-17F.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities